Hepion Pharmaceuticals reports developments around its transition into precision diagnostics, with a focus on blood-based tests for hepatocellular carcinoma and other disease areas. Company updates include the ctRNA biomarker assay licensed for early diagnosis and surveillance of HCC, the mSEPT9 PCR-based assay for liver cancer detection, and diagnostic test categories covering celiac disease, respiratory multiplex testing, H. pylori, and HCC.
Hepion news also covers public-company status changes and capital actions, including OTCQB trading, reverse stock split activity, Nasdaq delisting developments, leadership changes, stockholder voting matters, and the completed sale of rencofilstat-related patent assets, knowhow, clinical trial data, and drug product.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 17, 2023, Hepion Pharmaceuticals (NASDAQ:HEPA) announced that an abstract regarding its lead drug candidate, rencofilstat, will be presented by Chief Scientific Officer Daren Ure, PhD, at the American Association for Cancer Research Annual Meeting in Orlando, Florida, from April 15-19, 2023. The presentation, titled Rencofilstat Exerts a Dominant Role in Synergistic Anti-PD1-Combination Effects in a Fatty Liver Model of Hepatocellular Carcinoma, is scheduled for April 18, 2023, from 9:00 AM to 12:30 PM ET. Rencofilstat is currently in Phase 2 clinical trials for treating non-alcoholic steatohepatitis (NASH) and has received Fast Track and Orphan Drug designations from the FDA for its potential applications. The company utilizes its proprietary AI platform, AI-POWR™, for precision medicine in identifying responsive NASH patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) has appointed four renowned experts to its Scientific Advisory Board (SAB) as of March 30, 2023. This move enhances the company’s expertise in liver disease research and drug development. The new members are Dr. Rohit Loomba, Dr. Vlad Ratziu, Dr. Yury V. Popov, and Dr. Nikolai Naoumov, each bringing extensive backgrounds in hepatology.
Their experience will support Hepion's clinical programs for rencofilstat, aimed at treating NASH and HCC. Rencofilstat is currently in Phase 2 trials, with FDA Fast Track and Orphan Drug designations. Hepion also employs an AI platform, AI-POWR™, to optimize patient outcomes in its drug development.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that CEO Robert Foster and SVP Patrick Mayo will present in the free webinar "How Artificial Intelligence is Changing Drug Discovery" on March 23, 2023, at 1:00 PM ET. They will showcase their AI-POWR™ platform, which enhances drug target selection and clinical study design for fibrotic diseases like NASH and HCC. The AI-POWR™ platform integrates extensive clinical data with publicly available multi-omic databases, identifying biomarkers for patient response to rencofilstat, Hepion's lead drug. This innovative approach aims to optimize ongoing clinical trials and improve patient outcomes in drug development.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that Chief Medical Officer Todd Hobbs will present an update on the NASH clinical program for rencofilstat at the Global NASH Congress on March 3, 2023. The presentation will cover the ASCEND-NASH and ALTITUDE-NASH trials, focusing on timelines and progress. The ASCEND-NASH trial, involving 90 sites across North America and Europe, aims for complete enrollment within 12 months. The ALTITUDE-NASH trial reached full enrollment in December 2022, with topline results expected in Q2 2023. The FDA has granted Fast Track and Orphan Drug designations for rencofilstat, highlighting its potential for treating NASH and HCC.